GPP78
Based on 1 publication(s) in Google Scholar
GPP78 (CAY10618) is a potent Nampt inhibitor with an IC50 of 3.0 nM for nicotinamide adenine dinucleotide (NAD) depletion. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC50 of 3.8 nM by inducing autophagy. GPP78 has anti-cancer and anti-inflammatory effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.9%
- CAS No.: 1202580-59-3
- Formule: C27H29N5O
- Masse moléculaire:439.55
-
Stockage:
Solution, -20°C, 2 years
Publications Citing Use of MedChemExpress (MCE) GPP78
More
Activité biologique
Description
IC50 & Target
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | GI50 |
7.33 μM
Compound: 8
|
Growth inhibition of human 786-0 cells by sulforhodamine B assay
Growth inhibition of human 786-0 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| 786-0 | GI50 |
7.33 x 10-6 M
Compound: 8
|
Growth inhibition of human 786-0 cells by sulforhodamine B assay
Growth inhibition of human 786-0 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| A498 | GI50 |
1.59 x 10-5 M
Compound: 8
|
Growth inhibition of human A498 cells by sulforhodamine B assay
Growth inhibition of human A498 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| A549 | GI50 |
2.1 μM
Compound: 8
|
Growth inhibition of human A549 cells by sulforhodamine B assay
Growth inhibition of human A549 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| A549 | GI50 |
2.1 x 10-6 M
Compound: 8
|
Growth inhibition of human A549 cells by sulforhodamine B assay
Growth inhibition of human A549 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| ACHN | GI50 |
1.87 x 10-5 M
Compound: 8
|
Growth inhibition of human ACHN cells by sulforhodamine B assay
Growth inhibition of human ACHN cells by sulforhodamine B assay
|
[PMID: 19961183] |
| BT-549 | GI50 |
1.7 μM
Compound: 8
|
Growth inhibition of human BT549 cells by sulforhodamine B assay
Growth inhibition of human BT549 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| BT-549 | GI50 |
1.7 x 10-6 M
Compound: 8
|
Growth inhibition of human BT549 cells by sulforhodamine B assay
Growth inhibition of human BT549 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| CAKI-1 | GI50 |
7.76 x 10-7 M
Compound: 8
|
Growth inhibition of human Caki1 cells by sulforhodamine B assay
Growth inhibition of human Caki1 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| CAKI-1 | GI50 |
7.76 x 10-1 μM
Compound: 8
|
Growth inhibition of human Caki1 cells by sulforhodamine B assay
Growth inhibition of human Caki1 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| CCRF-CEM | GI50 |
3.28 μM
Compound: 8
|
Growth inhibition of human CCRF-CEM cells by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells by sulforhodamine B assay
|
[PMID: 19961183] |
| CCRF-CEM | GI50 |
3.28 x 10-6 M
Compound: 8
|
Growth inhibition of human CCRF-CEM cells by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells by sulforhodamine B assay
|
[PMID: 19961183] |
| COLO 205 | GI50 |
1.18 μM
Compound: 8
|
Growth inhibition of human COLO205 cells by sulforhodamine B assay
Growth inhibition of human COLO205 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| COLO 205 | GI50 |
1.18 x 10-6 M
Compound: 8
|
Growth inhibition of human COLO205 cells by sulforhodamine B assay
Growth inhibition of human COLO205 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| DU-145 | GI50 |
7.02 x 10-7 M
Compound: 8
|
Growth inhibition of human DU145 cells by sulforhodamine B assay
Growth inhibition of human DU145 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| DU-145 | GI50 |
7.02 x 10-1 μM
Compound: 8
|
Growth inhibition of human DU145 cells by sulforhodamine B assay
Growth inhibition of human DU145 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| EKVX | GI50 |
8.46 μM
Compound: 8
|
Growth inhibition of human EKVX cells by sulforhodamine B assay
Growth inhibition of human EKVX cells by sulforhodamine B assay
|
[PMID: 19961183] |
| EKVX | GI50 |
8.46 x 10-6 M
Compound: 8
|
Growth inhibition of human EKVX cells by sulforhodamine B assay
Growth inhibition of human EKVX cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HCC 2998 | GI50 |
7 x 10-7 M
Compound: 8
|
Growth inhibition of human HCC2998 cells by sulforhodamine B assay
Growth inhibition of human HCC2998 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HCC 2998 | GI50 |
7 x 10-1 μM
Compound: 8
|
Growth inhibition of human HCC2998 cells by sulforhodamine B assay
Growth inhibition of human HCC2998 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HCT-116 | GI50 |
4.03 x 10-8 M
Compound: 8
|
Growth inhibition of human HCT116 cells by sulforhodamine B assay
Growth inhibition of human HCT116 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HCT-116 | GI50 |
4.03 x 10-2 μM
Compound: 8
|
Growth inhibition of human HCT116 cells by sulforhodamine B assay
Growth inhibition of human HCT116 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HCT-15 | GI50 |
2.57 x 10-7 M
Compound: 8
|
Growth inhibition of human HCT15 cells by sulforhodamine B assay
Growth inhibition of human HCT15 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HCT-15 | GI50 |
2.57 x 10-1 μM
Compound: 8
|
Growth inhibition of human HCT15 cells by sulforhodamine B assay
Growth inhibition of human HCT15 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HOP-62 | GI50 |
2.38 x 10-5 M
Compound: 8
|
Growth inhibition of human HOP62 cells by sulforhodamine B assay
Growth inhibition of human HOP62 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HOP-92 | GI50 |
9.74 x 10-5 M
Compound: 8
|
Growth inhibition of human HOP92 cells by sulforhodamine B assay
Growth inhibition of human HOP92 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| Hs-578T | GI50 |
2.04 x 10-5 M
Compound: 8
|
Growth inhibition of human Hs 578T cells by sulforhodamine B assay
Growth inhibition of human Hs 578T cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HT-29 | GI50 |
4.6 x 10-7 M
Compound: 8
|
Growth inhibition of human HT-29 cells by sulforhodamine B assay
Growth inhibition of human HT-29 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| HT-29 | GI50 |
4.6 x 10-1 μM
Compound: 8
|
Growth inhibition of human HT-29 cells by sulforhodamine B assay
Growth inhibition of human HT-29 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| IGROV-1 | GI50 |
2.72 x 10-7 M
Compound: 8
|
Growth inhibition of human IGROV1 cells by sulforhodamine B assay
Growth inhibition of human IGROV1 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| IGROV-1 | GI50 |
2.72 x 10-1 μM
Compound: 8
|
Growth inhibition of human IGROV1 cells by sulforhodamine B assay
Growth inhibition of human IGROV1 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| KM12 | GI50 |
1.03 μM
Compound: 8
|
Growth inhibition of human KM12 cells by sulforhodamine B assay
Growth inhibition of human KM12 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| KM12 | GI50 |
1.03 x 10-6 M
Compound: 8
|
Growth inhibition of human KM12 cells by sulforhodamine B assay
Growth inhibition of human KM12 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| LOX IMVI | GI50 |
1.01 x 10-5 M
Compound: 8
|
Growth inhibition of human LOXIMVI cells by sulforhodamine B assay
Growth inhibition of human LOXIMVI cells by sulforhodamine B assay
|
[PMID: 19961183] |
| M14 | GI50 |
1.66 x 10-7 M
Compound: 8
|
Growth inhibition of human M14 cells by sulforhodamine B assay
Growth inhibition of human M14 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| M14 | GI50 |
1.66 x 10-1 μM
Compound: 8
|
Growth inhibition of human M14 cells by sulforhodamine B assay
Growth inhibition of human M14 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| Malme-3M | GI50 |
1.22 x 10-5 M
Compound: 8
|
Growth inhibition of human MALME-3M cells by sulforhodamine B assay
Growth inhibition of human MALME-3M cells by sulforhodamine B assay
|
[PMID: 19961183] |
| MCF7 | GI50 |
3.42 μM
Compound: 8
|
Growth inhibition of human MCF7 cells by sulforhodamine B assay
Growth inhibition of human MCF7 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| MCF7 | GI50 |
3.42 x 10-6 M
Compound: 8
|
Growth inhibition of human MCF7 cells by sulforhodamine B assay
Growth inhibition of human MCF7 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| MDA-MB-231 | GI50 |
2.09 x 10-5 M
Compound: 8
|
Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay
Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| MDA-MB-435 | GI50 |
3.99 x 10-7 M
Compound: 8
|
Growth inhibition of human MDA-MB-435 cells by sulforhodamine B assay
Growth inhibition of human MDA-MB-435 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| MDA-MB-435 | GI50 |
3.99 x 10-1 μM
Compound: 8
|
Growth inhibition of human MDA-MB-435 cells by sulforhodamine B assay
Growth inhibition of human MDA-MB-435 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| MDA-MB-468 | GI50 |
7.34 μM
Compound: 8
|
Growth inhibition of human MDA-MB-468 cells by sulforhodamine B assay
Growth inhibition of human MDA-MB-468 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| MDA-MB-468 | GI50 |
7.34 x 10-6 M
Compound: 8
|
Growth inhibition of human MDA-MB-468 cells by sulforhodamine B assay
Growth inhibition of human MDA-MB-468 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI/ADR-RES | GI50 |
8.14 x 10-8 M
Compound: 8
|
Growth inhibition of human NCI/ADR-RES cells by sulforhodamine B assay
Growth inhibition of human NCI/ADR-RES cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI/ADR-RES | GI50 |
8.14 x 10-2 μM
Compound: 8
|
Growth inhibition of human NCI/ADR-RES cells by sulforhodamine B assay
Growth inhibition of human NCI/ADR-RES cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI-H226 | GI50 |
1.55 x 10-5 M
Compound: 8
|
Growth inhibition of human NCI-H226 cells by sulforhodamine B assay
Growth inhibition of human NCI-H226 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI-H23 | GI50 |
1.51 x 10-5 M
Compound: 8
|
Growth inhibition of human NCI-H23 cells by sulforhodamine B assay
Growth inhibition of human NCI-H23 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI-H322M | GI50 |
2.31 x 10-5 M
Compound: 8
|
Growth inhibition of human NCI-H322M cells by sulforhodamine B assay
Growth inhibition of human NCI-H322M cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI-H460 | GI50 |
7.24 x 10-7 M
Compound: 8
|
Growth inhibition of human NCI-H460 cells by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI-H460 | GI50 |
7.24 x 10-1 μM
Compound: 8
|
Growth inhibition of human NCI-H460 cells by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI-H522 | GI50 |
9.14 x 10-8 M
Compound: 8
|
Growth inhibition of human NCI-H522 cells by sulforhodamine B assay
Growth inhibition of human NCI-H522 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| NCI-H522 | GI50 |
9.14 x 10-2 μM
Compound: 8
|
Growth inhibition of human NCI-H522 cells by sulforhodamine B assay
Growth inhibition of human NCI-H522 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| OVCAR-3 | GI50 |
5.19 μM
Compound: 8
|
Growth inhibition of human OVCAR-3 cells by sulforhodamine B assay
Growth inhibition of human OVCAR-3 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| OVCAR-3 | GI50 |
5.19 x 10-6 M
Compound: 8
|
Growth inhibition of human OVCAR-3 cells by sulforhodamine B assay
Growth inhibition of human OVCAR-3 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| OVCAR-4 | GI50 |
3.16 x 10-5 M
Compound: 8
|
Growth inhibition of human OVCAR4 cells by sulforhodamine B assay
Growth inhibition of human OVCAR4 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| OVCAR-5 | GI50 |
2.68 x 10-7 M
Compound: 8
|
Growth inhibition of human OVCAR5 cells by sulforhodamine B assay
Growth inhibition of human OVCAR5 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| OVCAR-5 | GI50 |
2.68 x 10-1 μM
Compound: 8
|
Growth inhibition of human OVCAR5 cells by sulforhodamine B assay
Growth inhibition of human OVCAR5 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| OVCAR-8 | GI50 |
5.74 x 10-8 M
Compound: 8
|
Growth inhibition of human OVCAR8 cells by sulforhodamine B assay
Growth inhibition of human OVCAR8 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| OVCAR-8 | GI50 |
5.74 x 10-2 μM
Compound: 8
|
Growth inhibition of human OVCAR8 cells by sulforhodamine B assay
Growth inhibition of human OVCAR8 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| PC-3 | GI50 |
4.67 x 10-7 M
Compound: 8
|
Growth inhibition of human PC3 cells by sulforhodamine B assay
Growth inhibition of human PC3 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| PC-3 | GI50 |
4.67 x 10-1 μM
Compound: 8
|
Growth inhibition of human PC3 cells by sulforhodamine B assay
Growth inhibition of human PC3 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| RXF 393 | GI50 |
1 x 10-4 M
Compound: 8
|
Growth inhibition of human RXF393 cells by sulforhodamine B assay
Growth inhibition of human RXF393 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SF-268 | GI50 |
2.47 x 10-5 M
Compound: 8
|
Growth inhibition of human SF268 cells by sulforhodamine B assay
Growth inhibition of human SF268 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SF-295 | GI50 |
6.55 x 10-7 M
Compound: 8
|
Growth inhibition of human SF295 cells by sulforhodamine B assay
Growth inhibition of human SF295 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SF-295 | GI50 |
6.55 x 10-1 μM
Compound: 8
|
Growth inhibition of human SF295 cells by sulforhodamine B assay
Growth inhibition of human SF295 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SF-539 | GI50 |
6.18 x 10-8 M
Compound: 8
|
Growth inhibition of human SF539 cells by sulforhodamine B assay
Growth inhibition of human SF539 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SF-539 | GI50 |
6.18 x 10-2 μM
Compound: 8
|
Growth inhibition of human SF539 cells by sulforhodamine B assay
Growth inhibition of human SF539 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SH-SY5Y | IC50 |
3 nM
Compound: 8
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction of total cellular NAD(P) level
Cytotoxicity against human SH-SY5Y cells assessed as reduction of total cellular NAD(P) level
|
[PMID: 19961183] |
| SH-SY5Y | IC50 |
3.8 nM
Compound: 8
|
Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 19961183] |
| SH-SY5Y | IC50 |
3.8 nM
Compound: 5
|
Cytotoxicity against human SH-SY5Y cells
Cytotoxicity against human SH-SY5Y cells
|
[PMID: 21080724] |
| SK-MEL-2 | GI50 |
1.28 x 10-5 M
Compound: 8
|
Growth inhibition of human SK-MEL-2 cells by sulforhodamine B assay
Growth inhibition of human SK-MEL-2 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SK-MEL-28 | GI50 |
1.59 μM
Compound: 8
|
Growth inhibition of human SK-MEL-28 cells by sulforhodamine B assay
Growth inhibition of human SK-MEL-28 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SK-MEL-28 | GI50 |
1.59 x 10-6 M
Compound: 8
|
Growth inhibition of human SK-MEL-28 cells by sulforhodamine B assay
Growth inhibition of human SK-MEL-28 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SK-MEL-5 | GI50 |
2.64 x 10-5 M
Compound: 8
|
Growth inhibition of human SK-MEL-5 cells by sulforhodamine B assay
Growth inhibition of human SK-MEL-5 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SK-OV-3 | GI50 |
2.05 x 10-5 M
Compound: 8
|
Growth inhibition of human SKOV3 cells by sulforhodamine B assay
Growth inhibition of human SKOV3 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SN12C | GI50 |
4.26 x 10-8 M
Compound: 8
|
Growth inhibition of human SN12C cells by sulforhodamine B assay
Growth inhibition of human SN12C cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SN12C | GI50 |
4.26 x 10-2 μM
Compound: 8
|
Growth inhibition of human SN12C cells by sulforhodamine B assay
Growth inhibition of human SN12C cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SNB-19 | GI50 |
4.5 x 10-7 M
Compound: 8
|
Growth inhibition of human SNB19 cells by sulforhodamine B assay
Growth inhibition of human SNB19 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SNB-19 | GI50 |
4.5 x 10-1 μM
Compound: 8
|
Growth inhibition of human SNB19 cells by sulforhodamine B assay
Growth inhibition of human SNB19 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SNB-75 | GI50 |
2.98 x 10-5 M
Compound: 8
|
Growth inhibition of human SNB75 cells by sulforhodamine B assay
Growth inhibition of human SNB75 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SW-620 | GI50 |
6.15 x 10-8 M
Compound: 8
|
Growth inhibition of human SW620 cells by sulforhodamine B assay
Growth inhibition of human SW620 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| SW-620 | GI50 |
6.15 x 10-2 μM
Compound: 8
|
Growth inhibition of human SW620 cells by sulforhodamine B assay
Growth inhibition of human SW620 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| T47D | GI50 |
1.23 μM
Compound: 8
|
Growth inhibition of human T47D cells by sulforhodamine B assay
Growth inhibition of human T47D cells by sulforhodamine B assay
|
[PMID: 19961183] |
| T47D | GI50 |
1.23 x 10-6 M
Compound: 8
|
Growth inhibition of human T47D cells by sulforhodamine B assay
Growth inhibition of human T47D cells by sulforhodamine B assay
|
[PMID: 19961183] |
| TK-10 | GI50 |
1.82 x 10-5 M
Compound: 8
|
Growth inhibition of human TK10 cells by sulforhodamine B assay
Growth inhibition of human TK10 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| U-251 | GI50 |
5.21 x 10-7 M
Compound: 8
|
Growth inhibition of human U251 cells by sulforhodamine B assay
Growth inhibition of human U251 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| U-251 | GI50 |
5.21 x 10-1 μM
Compound: 8
|
Growth inhibition of human U251 cells by sulforhodamine B assay
Growth inhibition of human U251 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| UACC-257 | GI50 |
1.33 x 10-5 M
Compound: 8
|
Growth inhibition of human UACC257 cells by sulforhodamine B assay
Growth inhibition of human UACC257 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| UACC-62 | GI50 |
1.33 x 10-5 M
Compound: 8
|
Growth inhibition of human UACC62 cells by sulforhodamine B assay
Growth inhibition of human UACC62 cells by sulforhodamine B assay
|
[PMID: 19961183] |
| UO-31 | GI50 |
1.69 x 10-5 M
Compound: 8
|
Growth inhibition of human UO31 cells by sulforhodamine B assay
Growth inhibition of human UO31 cells by sulforhodamine B assay
|
[PMID: 19961183] |
In Vitro
GPP78 (Compound 8; 10 nM; 24-40 hours; SH-SY5Y cells) treatment with cells, punctate staining of LC3-II and the formation of autophagolysosomes are observable. LC3-II is membrane-bound and is present in autophagosomes[1].
GPP78 (Compound 8) inhibits the growth of most cell lines tested, with nanomolar potency (GI50) in cell lines derived from leukemia, lung, CNS, colon, melanoma, ovarian, renal, and prostate cancers. GPP78 appears truly cytotoxic in melanoma cell lines, while in the others it is mainly cytostatic[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SH-SY5Y cells
-
Concentration:10 nM
-
Incubation Time:24 hours, 40 hours
-
Result:Punctate staining of LC3-II and the formation of autophagolysosomes were observable.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male adult CD1 mice (25-30 g) with spinal cord injury (SCI)[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; daily; 1 hour or 6 hours after SCI; for 19 days
-
Result:Significantly reduced the demyelination associated with SCI. And significantly ameliorated the functional deficits induced by SCI.
Chemical Information
-
CAS No. 1202580-59-3
-
Appearance Liquid
-
Masse moléculaire 439.55
-
Formule C27H29N5O
-
Color Colorless to light yellow
-
SMILES
O=C(CCCCCCCN1N=NC(C2=CN=CC=C2)=C1)NC3=CC=CC=C3C4=CC=CC=C4
-
Synonyms
CAY10618
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Solution, -20°C, 2 years
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Signal
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. [Abstract]2021 Jun 8;14(686):eabc7405. PMID: 34103421
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Colombano G, et al. A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J Med Chem. 2010 Jan 28;53(2):616-23. [Content Brief]
[2]. Esposito E, et al. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. J Neuroinflammation. 2012 Apr 10;9:66. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)